Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 333

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 333
---

    -

    $
    18,550.00

    4/13/2028

    Former President, Chief Executive Officer and Interim   Chief Financial Officer(5)

    2

    -

    $
    10,673.25

    11/8/2028

    20

    -

    $
    1,067.50

    9/5/2029

    22

    -

    $
    1,067.50

    9/5/2029

    68

    -

    $
    2,975.00

    9/15/2030

    57

    -

    $
    2,170.00

    9/22/2031

    2,010

    -

    $
    1,680.00

    11/8/2031

    686

    -

    $
    307.48

    8/1/2032

    661

    -

    $
    162.93

    8/30/2033

(1)This option vests, in arrears, in three equal annual installments over three years from the grant date of April 7, 2023, subject to his continuous service on each vesting date.

104

(2)This option vests, in arrears, in three equal annual installments over three years from the grant date of November 15, 2022, subject to his continuous service on each vesting date.

(3)This option vests, in arrears, in three equal annual installments over three years from the grant date of February 28, 2023, subject to his continuous service on each vesting date.

(4)This option vests, in arrears, in three equal annual installments over three years from the grant date of November 12, 2024, subject to his continuous service on each vesting date.

(5)Pursuant to the Hoffman Amendment, all of Mr. Hoffman's outstanding options vested in full on October 4, 2024. 

Potential Payments Upon Termination or Change in Control

Under the employment agreements with the NEOs, in the event the NEO is terminated by us other than for “Cause” or by the NEO for “Good Reason,” the NEO will be eligible for the following severance benefits if he executes a release of